Influência de Harpagophytum procumbens sobre parâmetros comportamentais e moleculares em um modelo de discinesia orofacial em ratos
Autor(a) principal: | |
---|---|
Data de Publicação: | 2017 |
Tipo de documento: | Tese |
Idioma: | por |
Título da fonte: | Manancial - Repositório Digital da UFSM |
dARK ID: | ark:/26339/001300000nbjc |
Texto Completo: | http://repositorio.ufsm.br/handle/1/18437 |
Resumo: | Fluphenazine is a typical antipsychotic used for the treatment of schizophrenia. However, its chronic use has been related to the appearance of extrapyramidal side effects, such as tardive dyskinesia (TD). Studies suggest the involvement of neuroinflammation as well as oxidative stress (OS), as possible causes for the onset of DT, which can also lead to dopaminergic neurodegeneration. Harpagophytum procumbens (HP) is a herbal medicine used in the clinic mainly due to its anti-inflammatory effects. Thus, the objective of this study was to evaluate the influence of HP on behavioral, biochemical and molecular parameters in fluphenazine-induced orofacial dyskinesia (OD) model in rats. First, we analyzed several fractions of HP by high performance liquid chromatography and performed the radical-scavenging activity DPPH assay. In order to choose a fraction that presented greater amount of harpagoside and that had a good antioxidant activity in vitro, where we chose the ethyl acetate fraction of H. procumbens (EAF HP). Thus, we verified the effect of EAF HP (10, 30 and 100 mg / kg-21 days) on fluphenazine-induced OD (25 mg / kg single dose) in rats through motor behavioral parameters. In addition, we performed biochemical serological analyzes, OS parameters (in liver, kidney, cortex and striatum), proinflammatory cytokines (in striatum and cortex), immunoreactivity of tyrosine hydroxylase (TH), dopamine transporter (DAT), dopamine receptor subtype D2 (DRD2), glutamate decarboxylase (GAD) and cyclooxygenase 2 (COX 2) (in striatum). Chronic administration of fluphenazine significantly increased vacuos chewing movements (VCMs) at all analyzed times (2, 7, 14 and 21 days) and this increase was inhibited by EAF HP, especially at the dose of 30 mg / kg, on days 7, 14 and 21. Fluphenazine decreased locomotion and exploratory activity, however EAF HP did not protect against this change. Fluphenazine induced OS identified by changes in catalase activity and levels of reactive oxygen / nitrogen species (RS) in the cortex and striatum. In addition, it increased all proinflammatory cytokines, and showed a tendency to increase COX 2 levels. However, it did not modify the immunoreactivity of TH, DAT, DRD2 and GAD. The effects of fluphenazine were reduced by administration of HP EAF especially in the striatum, which structure is related to motor control. Moreover, this fraction proved to be safe, because none of the doses tested showed a change in the biochemical parameters in serum and OS in the liver and kidneys of animals. Our results suggest the involvement of OS and neuroinflammation fluphenazine-induced in the development of OD in rats and points to EAF HP as a promising therapeutic agent for the treatment of oral involuntary movements. |
id |
UFSM_747fc1c865d265d6956849160f0496d8 |
---|---|
oai_identifier_str |
oai:repositorio.ufsm.br:1/18437 |
network_acronym_str |
UFSM |
network_name_str |
Manancial - Repositório Digital da UFSM |
repository_id_str |
|
spelling |
Influência de Harpagophytum procumbens sobre parâmetros comportamentais e moleculares em um modelo de discinesia orofacial em ratosInfluence of Harpagophytum procumbens on behavioral and molecular parameters in a model of orofacial dyskinesia in ratsGarra do diaboFlufenazinaDiscinesia tardiaNeuroinflamaçãoEstresse oxidativoDevil's clawFluphenazineTardive dyskinesiaNeuroinflammationOxidative stressCNPQ::CIENCIAS DA SAUDE::FARMACIAFluphenazine is a typical antipsychotic used for the treatment of schizophrenia. However, its chronic use has been related to the appearance of extrapyramidal side effects, such as tardive dyskinesia (TD). Studies suggest the involvement of neuroinflammation as well as oxidative stress (OS), as possible causes for the onset of DT, which can also lead to dopaminergic neurodegeneration. Harpagophytum procumbens (HP) is a herbal medicine used in the clinic mainly due to its anti-inflammatory effects. Thus, the objective of this study was to evaluate the influence of HP on behavioral, biochemical and molecular parameters in fluphenazine-induced orofacial dyskinesia (OD) model in rats. First, we analyzed several fractions of HP by high performance liquid chromatography and performed the radical-scavenging activity DPPH assay. In order to choose a fraction that presented greater amount of harpagoside and that had a good antioxidant activity in vitro, where we chose the ethyl acetate fraction of H. procumbens (EAF HP). Thus, we verified the effect of EAF HP (10, 30 and 100 mg / kg-21 days) on fluphenazine-induced OD (25 mg / kg single dose) in rats through motor behavioral parameters. In addition, we performed biochemical serological analyzes, OS parameters (in liver, kidney, cortex and striatum), proinflammatory cytokines (in striatum and cortex), immunoreactivity of tyrosine hydroxylase (TH), dopamine transporter (DAT), dopamine receptor subtype D2 (DRD2), glutamate decarboxylase (GAD) and cyclooxygenase 2 (COX 2) (in striatum). Chronic administration of fluphenazine significantly increased vacuos chewing movements (VCMs) at all analyzed times (2, 7, 14 and 21 days) and this increase was inhibited by EAF HP, especially at the dose of 30 mg / kg, on days 7, 14 and 21. Fluphenazine decreased locomotion and exploratory activity, however EAF HP did not protect against this change. Fluphenazine induced OS identified by changes in catalase activity and levels of reactive oxygen / nitrogen species (RS) in the cortex and striatum. In addition, it increased all proinflammatory cytokines, and showed a tendency to increase COX 2 levels. However, it did not modify the immunoreactivity of TH, DAT, DRD2 and GAD. The effects of fluphenazine were reduced by administration of HP EAF especially in the striatum, which structure is related to motor control. Moreover, this fraction proved to be safe, because none of the doses tested showed a change in the biochemical parameters in serum and OS in the liver and kidneys of animals. Our results suggest the involvement of OS and neuroinflammation fluphenazine-induced in the development of OD in rats and points to EAF HP as a promising therapeutic agent for the treatment of oral involuntary movements.Coordenação de Aperfeiçoamento de Pessoal de Nível Superior - CAPESA flufenazina é um antipsicótico típico utilizado para o tratamento da esquizofrenia. No entanto, o seu uso crônico tem sido relacionado com o aparecimento de efeitos colaterais extrapiramidais, como a discinesia tardia (DT). Estudos sugerem o envolvimento da neuroinflamação, bem como o estresse oxidativo (EO), como possíveis causas para o aparecimento da DT, o que também pode levar à neurodegeneração dopaminérgica. O Harpagophytum procumbens (HP) é um fitoterápico utilizado na clínica devido principalmente aos seus efeitos anti-inflamatórios. Desta forma o objetivo deste trabalho foi avaliar a influência do HP sobre parâmetros comportamentais, bioquímicos e moleculares em modelo de discinesia orofacial (DO) induzida por flufenazina em ratos. Primeiramente analisamos várias frações de HP por cromatografia líquida de alta eficiência e realizamos o teste de scavenger do radical DPPH, a fim de eleger uma fração que apresentasse maior quantidade de harpagosídeo e que tivesse uma boa atividade antioxidante in vitro, sendo então eleita a fração de acetato de etila de H. procumbens (EAF HP). Desta forma, verificamos o efeito da EAF HP (10; 30 e 100 mg/kg- 21dias) sobre a DO induzida por flufenazina (25 mg/kg dose única) em ratos através da análise de parâmetros comportamentais motores. Além disso, realizamos análises bioquímicas sorológicas, parâmetros de EO (no fígado, rim, córtex e estriado), citocinas pró-inflamatórias (no estriado e córtex), imunoreatividade da tirosina hidroxilase (TH), do transportador de dopamina (DAT), do receptor dopaminérgico D2 (DRD2), do glutamato descarboxilase (GAD) e da ciclooxigenase 2 (COX 2) (no estriado). A administração crônica de flufenazina aumentou significativamente os movimentos de mascar no vazio (MMVs) em todos tempos analisados (2, 7, 14 e 21 dias) e esse aumento foi inibido pela EAF HP, especialmente na dose de 30 mg/kg, nos dias 7, 14 e 21. A flufenazina diminuiu a locomoção e atividade exploratória, no entanto EAF HP não foi capaz de proteger contra esta alteração. A flufenazina induziu EO identificado por alterações na atividade da catalase e nos níveis de de oxigênio/nitrogênio (ER) no córtex e estriado. Além disso, aumentou todas as citocinas pro-inflamatórias, e apresentou tendência em aumentar os níveis de COX 2. Contudo, não modificou a imunoreatividade da TH, DAT, DRD2 e GAD. Os efeitos da flufenazina foram reduzidos pela administração da EAF HP especialmente no estriado, estrutura que está relacionado com o controle motor. Além disso, esta fração se mostrou segura, pois nenhuma das doses testadas causou alteração nos parâmetros bioquímicos no soro e de EO no fígado e rins dos animais. Os nossos resultados sugerem o envolvimento do EO e da neuroinflamação induzida pela flufenazina no desenvolvimento da DO em ratos e aponta a EAF HP como um agente terapêutico promissor para o tratamento de movimentos involuntários orais.Universidade Federal de Santa MariaBrasilFarmacologiaUFSMPrograma de Pós-Graduação em FarmacologiaCentro de Ciências da SaúdeWagner, Carolinehttp://lattes.cnpq.br/4004565241849091Sagrillo, Michele Roratohttp://lattes.cnpq.br/2566285176244747Franco, Jeferson Luishttp://lattes.cnpq.br/1680065573338339Rosemberg, Denis Broockhttp://lattes.cnpq.br/7713953979203056Burger, Marilise Escobarhttp://lattes.cnpq.br/9128090974948413Schaffer, Larissa Finger2019-09-26T20:36:03Z2019-09-26T20:36:03Z2017-02-18info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/doctoralThesisapplication/pdfhttp://repositorio.ufsm.br/handle/1/18437ark:/26339/001300000nbjcporAttribution-NonCommercial-NoDerivatives 4.0 Internationalhttp://creativecommons.org/licenses/by-nc-nd/4.0/info:eu-repo/semantics/openAccessreponame:Manancial - Repositório Digital da UFSMinstname:Universidade Federal de Santa Maria (UFSM)instacron:UFSM2019-09-27T06:02:30Zoai:repositorio.ufsm.br:1/18437Biblioteca Digital de Teses e Dissertaçõeshttps://repositorio.ufsm.br/ONGhttps://repositorio.ufsm.br/oai/requestatendimento.sib@ufsm.br||tedebc@gmail.comopendoar:2019-09-27T06:02:30Manancial - Repositório Digital da UFSM - Universidade Federal de Santa Maria (UFSM)false |
dc.title.none.fl_str_mv |
Influência de Harpagophytum procumbens sobre parâmetros comportamentais e moleculares em um modelo de discinesia orofacial em ratos Influence of Harpagophytum procumbens on behavioral and molecular parameters in a model of orofacial dyskinesia in rats |
title |
Influência de Harpagophytum procumbens sobre parâmetros comportamentais e moleculares em um modelo de discinesia orofacial em ratos |
spellingShingle |
Influência de Harpagophytum procumbens sobre parâmetros comportamentais e moleculares em um modelo de discinesia orofacial em ratos Schaffer, Larissa Finger Garra do diabo Flufenazina Discinesia tardia Neuroinflamação Estresse oxidativo Devil's claw Fluphenazine Tardive dyskinesia Neuroinflammation Oxidative stress CNPQ::CIENCIAS DA SAUDE::FARMACIA |
title_short |
Influência de Harpagophytum procumbens sobre parâmetros comportamentais e moleculares em um modelo de discinesia orofacial em ratos |
title_full |
Influência de Harpagophytum procumbens sobre parâmetros comportamentais e moleculares em um modelo de discinesia orofacial em ratos |
title_fullStr |
Influência de Harpagophytum procumbens sobre parâmetros comportamentais e moleculares em um modelo de discinesia orofacial em ratos |
title_full_unstemmed |
Influência de Harpagophytum procumbens sobre parâmetros comportamentais e moleculares em um modelo de discinesia orofacial em ratos |
title_sort |
Influência de Harpagophytum procumbens sobre parâmetros comportamentais e moleculares em um modelo de discinesia orofacial em ratos |
author |
Schaffer, Larissa Finger |
author_facet |
Schaffer, Larissa Finger |
author_role |
author |
dc.contributor.none.fl_str_mv |
Wagner, Caroline http://lattes.cnpq.br/4004565241849091 Sagrillo, Michele Rorato http://lattes.cnpq.br/2566285176244747 Franco, Jeferson Luis http://lattes.cnpq.br/1680065573338339 Rosemberg, Denis Broock http://lattes.cnpq.br/7713953979203056 Burger, Marilise Escobar http://lattes.cnpq.br/9128090974948413 |
dc.contributor.author.fl_str_mv |
Schaffer, Larissa Finger |
dc.subject.por.fl_str_mv |
Garra do diabo Flufenazina Discinesia tardia Neuroinflamação Estresse oxidativo Devil's claw Fluphenazine Tardive dyskinesia Neuroinflammation Oxidative stress CNPQ::CIENCIAS DA SAUDE::FARMACIA |
topic |
Garra do diabo Flufenazina Discinesia tardia Neuroinflamação Estresse oxidativo Devil's claw Fluphenazine Tardive dyskinesia Neuroinflammation Oxidative stress CNPQ::CIENCIAS DA SAUDE::FARMACIA |
description |
Fluphenazine is a typical antipsychotic used for the treatment of schizophrenia. However, its chronic use has been related to the appearance of extrapyramidal side effects, such as tardive dyskinesia (TD). Studies suggest the involvement of neuroinflammation as well as oxidative stress (OS), as possible causes for the onset of DT, which can also lead to dopaminergic neurodegeneration. Harpagophytum procumbens (HP) is a herbal medicine used in the clinic mainly due to its anti-inflammatory effects. Thus, the objective of this study was to evaluate the influence of HP on behavioral, biochemical and molecular parameters in fluphenazine-induced orofacial dyskinesia (OD) model in rats. First, we analyzed several fractions of HP by high performance liquid chromatography and performed the radical-scavenging activity DPPH assay. In order to choose a fraction that presented greater amount of harpagoside and that had a good antioxidant activity in vitro, where we chose the ethyl acetate fraction of H. procumbens (EAF HP). Thus, we verified the effect of EAF HP (10, 30 and 100 mg / kg-21 days) on fluphenazine-induced OD (25 mg / kg single dose) in rats through motor behavioral parameters. In addition, we performed biochemical serological analyzes, OS parameters (in liver, kidney, cortex and striatum), proinflammatory cytokines (in striatum and cortex), immunoreactivity of tyrosine hydroxylase (TH), dopamine transporter (DAT), dopamine receptor subtype D2 (DRD2), glutamate decarboxylase (GAD) and cyclooxygenase 2 (COX 2) (in striatum). Chronic administration of fluphenazine significantly increased vacuos chewing movements (VCMs) at all analyzed times (2, 7, 14 and 21 days) and this increase was inhibited by EAF HP, especially at the dose of 30 mg / kg, on days 7, 14 and 21. Fluphenazine decreased locomotion and exploratory activity, however EAF HP did not protect against this change. Fluphenazine induced OS identified by changes in catalase activity and levels of reactive oxygen / nitrogen species (RS) in the cortex and striatum. In addition, it increased all proinflammatory cytokines, and showed a tendency to increase COX 2 levels. However, it did not modify the immunoreactivity of TH, DAT, DRD2 and GAD. The effects of fluphenazine were reduced by administration of HP EAF especially in the striatum, which structure is related to motor control. Moreover, this fraction proved to be safe, because none of the doses tested showed a change in the biochemical parameters in serum and OS in the liver and kidneys of animals. Our results suggest the involvement of OS and neuroinflammation fluphenazine-induced in the development of OD in rats and points to EAF HP as a promising therapeutic agent for the treatment of oral involuntary movements. |
publishDate |
2017 |
dc.date.none.fl_str_mv |
2017-02-18 2019-09-26T20:36:03Z 2019-09-26T20:36:03Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/doctoralThesis |
format |
doctoralThesis |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://repositorio.ufsm.br/handle/1/18437 |
dc.identifier.dark.fl_str_mv |
ark:/26339/001300000nbjc |
url |
http://repositorio.ufsm.br/handle/1/18437 |
identifier_str_mv |
ark:/26339/001300000nbjc |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.rights.driver.fl_str_mv |
Attribution-NonCommercial-NoDerivatives 4.0 International http://creativecommons.org/licenses/by-nc-nd/4.0/ info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
Attribution-NonCommercial-NoDerivatives 4.0 International http://creativecommons.org/licenses/by-nc-nd/4.0/ |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Universidade Federal de Santa Maria Brasil Farmacologia UFSM Programa de Pós-Graduação em Farmacologia Centro de Ciências da Saúde |
publisher.none.fl_str_mv |
Universidade Federal de Santa Maria Brasil Farmacologia UFSM Programa de Pós-Graduação em Farmacologia Centro de Ciências da Saúde |
dc.source.none.fl_str_mv |
reponame:Manancial - Repositório Digital da UFSM instname:Universidade Federal de Santa Maria (UFSM) instacron:UFSM |
instname_str |
Universidade Federal de Santa Maria (UFSM) |
instacron_str |
UFSM |
institution |
UFSM |
reponame_str |
Manancial - Repositório Digital da UFSM |
collection |
Manancial - Repositório Digital da UFSM |
repository.name.fl_str_mv |
Manancial - Repositório Digital da UFSM - Universidade Federal de Santa Maria (UFSM) |
repository.mail.fl_str_mv |
atendimento.sib@ufsm.br||tedebc@gmail.com |
_version_ |
1815172366778499072 |